The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]
Recruiting now
Conditions studied: Small Cell Lung Cancers, Neuroendocrine Carcinoma
In brief
This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial. This procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood. Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue. Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH. Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.
Key facts
- Study ID
- NCT02688894
- Run by
- Samsung Medical Center
- People needed
- 797
- Starts
- 2016-04-29
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-04-28
Who can join
Age: 20 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provision of fully informed consent prior to any study specific procedures.
- Patients must be ≥20 years of age.
- Histologically or cytologically confirmed Small cell lung cancers
- ECOG performance status of 0 to 2
- Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment
- Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis
You may not qualify if…
- More than two prior chemotherapy regimen for the treatment of small cell lung cancer
- Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)
- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.
Where it is running
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Gachon University Gil Medical Center — Incheon, South Korea
- Seoul National University Bundang Hospital — Seongnam, South Korea
- VHS Medical Center — Seoul, South Korea
- Chungbuk University Hospital — Taebuk, South Korea
- Ulsan University Hospital — Ulsan, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.